ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Nov 19, 2018
Dropping Coverage of the Securities Research Industry
Image Source: Andreas Poike. Valuentum is dropping coverage of the securities research industry to allocate resources elsewhere.
Oct 4, 2018
Constellation Sets Optimistic Tone, Outlines Cannabis Opportunity
Image Source: Constellation Brands. The producer of beer, wine and spirits reported excellent second quarter fiscal 2019 results and described cannabis as a “once-a-century disruptive market transition.” Without a doubt, the opportunity in cannabis looks tremendous, but the landscape is fast-evolving. We think Constellation will be a long-term winner in the space, but outsize profits in cannabis may be tough to come by initially.
Aug 23, 2018
In the News: Pot, Pop, and Pricing Wars
Let’s take a look at some of the hottest topics around the markets.
Jul 1, 2018
Our Stock Reports on Securities Research Firms
Image Source: Andreas Poike. We've discontinued coverage of the following companies: DNB, FDS, MCO, MORN, SPGI, TRI, VALU.
Apr 5, 2018
Walgreens Boots Alliance Remains at the Crossroads of a Rapidly-Evolving Healthcare Landscape
Image Source: Walgreens 2Q 2018 Earnings Release. The evolving healthcare landscape has been dealing with the threat of a disruptive new competitor entering the market and considerable political risk. Though the need for healthcare remains impervious to economic forces, a clear deflationary trend has descended on the industry that has affected many of the well-entrenched participants. Let’s examine Walgreens Boots Alliance for clues that a shift in sentiment may have occurred in this well known, yet beleaguered sector.
Mar 15, 2018
Cigna, Express, and the Unwinding of the PBM Market
Image Source: Cigna. Given its track record of creative destruction, when Amazon plans to enter a particular line of business, it presents an ominous threat to incumbents. What is often overlooked, too, is that Amazon is more than willing to try new verticals—if they prove promising, additional assets will be devoted to the new line of business, often with fawning media coverage. If Amazon is unsuccessful in its endeavor, however, then it seems as though it will “fail fast” and shut down the project and move on. We found the recent announcement of a joint venture to tackle the healthcare industry as particularly noteworthy.
Feb 27, 2018
Buffett’s Berkshire, Corporate Buybacks on Pace for Record; Lithium, Steel Prices on the Move
Image Source: Berkshire Hathaway, Shareholder Letter (2017). “Fifteen common stock investments at year end that had the largest market value.” “The less the prudence with which others conduct their affairs, the greater the prudence with which we must conduct our own.” – Warren Buffett, Shareholder Letter (2017)
Jan 27, 2018
Dividend Increases/Decreases for the Week Ending January 26
Let's take a look at companies that raised/lowered their dividend this week.
Dec 12, 2017
CVS Health at the Crossroads, Too Much Debt
Image Source: CVS Health. We have been disappointed with the lack progress displayed by CVS Health thus far in 2017. We knew the business was entering into an earnings trough as a result of key contract losses, but recent events have unfolded that, in our view, have lessened the attractiveness of its business model, to a meaningful degree. Let’s talk more about what’s happening at CVS Health, the changing PBM market, Amazon’s threat, and too much leverage. We’re not overreacting, but we’re not happy either.
Nov 18, 2017
Valuentum's Highest-Rated Economic Castles
Image Source: Dunrobin Castle; Golspie, Sutherland, John Haslam. A look at some of the highest-rated Economic Castles in our coverage universe.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.